Search News Archives
Special Offers and Promotions
Brochures & Literature
Conferences | Events
Gyros AB Extends Capabilities of Gyrolab Automated Immunoassay Platform with New Affinity Software Module
New software module supports in-solution affinity characterization at nanoliter-scale
Gyros AB, a pioneer in miniaturizing and automating immunoassays at nanoliter-scale, today announced the release of Gyrolab™ Affinity Software Module, which is available on both Gyrolab xP workstation and the recently launched single CD Gyrolab xPlore. The new, intuitive software module enables users to easily set up and run in-solution affinity determinations of up to 14 interacting pairs in parallel in just one hour.
Characterization of antibody-target binding is a critical element in the discovery and development of therapeutic antibodies. The desirable characteristics of effective therapeutic antibodies often include high affinity to the target, which can lower dosage, improve healthcare and reduce costs. Measuring affinity therefore plays a key role from discovery to manufacturing.
Technologies commonly used for affinity measurements include real-time, surface-based measurements such as surface plasmon resonance (SPR), bio-layer interferometry (BLI), and quartz crystal microbalance (QCM). These technologies often exhibit constraints in analyzing slow dissociation kinetics, which limits their ability to measure the high affinity dissociation constants (KD) that characterize modern biotherapeutics.
Gyros’ technology allows biotherapeutic developers to determine accurate KD of un-modified substances down to low picomolar levels by measuring free interactants in equilibrated solutions. The flow-through affinity column format in Gyrolab CDs is ideal for in-solution affinity determination, as interaction times of only a few seconds avoid the equilibrium shifts that are inherent in assays requiring longer incubation times.
“Gyrolab systems are already increasing productivity for biopharmaceutical companies and their CRO and CMO partners,” said Dan Calvo, CEO, Gyros AB. “The addition of our new Affinity Software Module extends the utility of the system for antibody quantification and characterization at various stages during the development and manufacturing of biotherapeutics.”